Skip to main content

CGEN

Stock
Health Care
Biotechnology

Performance overview

CGEN Price
Price Chart

Forward-looking statistics

Beta
1.56
Risk
83.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Company info

SectorHealth Care
IndustryBiotechnology
Employees43
Market cap$188.9M

Fundamentals

Enterprise value$63.3M
Revenue$27.6M
Revenue per employee
Profit margin-51.27%
Debt to equity4.85

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.16
Dividend per share
Revenue per share$0.31
Avg trading volume (30 day)$370K
Avg trading volume (10 day)$258K
Put-call ratio

Macro factor sensitivity

Growth+4.7
Credit+5.2
Liquidity-3.2
Inflation+0.7
Commodities+1.7
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio-16.00
Price to sales5.97
P/E Ratio-16.00
Enterprise Value to Revenue2.30
Price to book2.84

Upcoming events

Next earnings dayMay 19, 2025
Next dividend day
Ex. dividend day

News

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.

Zacks Investment Research (May 19, 2025)
Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial

AstraZeneca Plc's (NASDAQ: AZN) bispecific antibody derived from Compugen Ltd's (NASDAQ: CGEN) COM902 will advance into clinical development.  AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.

Benzinga (August 19, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free